Pneumocystis jirovecii pneumonia (PCP)

After this note, you should be able to understand the key aspects of PCP. Always check drug doses and local protocols against the Kenya MoH guidelines and your hospital formulary.

Definition

Pneumocystis jirovecii pneumonia (PCP) is a life-threatening opportunistic fungal infection of the lungs, primarily affecting immunocompromised individuals. It is caused by the fungus Pneumocystis jirovecii (formerly Pneumocystis carinii).

Anatomy and physiology you need

Understanding PCP requires a basic grasp of:

• Alveolar-capillary unit: The primary site of gas exchange in the lungs. PCP causes inflammation and exudate within the alveoli, impairing oxygen diffusion.
• Type I pneumocytes: Flat cells forming the alveolar lining, crucial for gas exchange.
• Type II pneumocytes: Cuboidal cells that produce surfactant, reducing alveolar surface tension and preventing collapse. PCP can damage these cells, leading to reduced surfactant and alveolar collapse.
• Pulmonary interstitium: The space between the alveolar epithelium and capillary endothelium. PCP often causes interstitial inflammation and thickening.
• Immune system (specifically T-lymphocytes): CD4+ T-lymphocytes are central to cell-mediated immunity, particularly against intracellular pathogens and fungi like Pneumocystis jirovecii. Their depletion is the main risk factor for PCP.

Causes and risk factors

PCP is caused by the fungus Pneumocystis jirovecii. It is an opportunistic infection, meaning it primarily affects individuals with compromised immune systems.

The main risk factors include:

• HIV infection: This is the most common risk factor. The risk of PCP significantly increases as the CD4+ T-lymphocyte count drops.
  • CD4 count < 200 cells/µL: This is the critical threshold for increased risk. Most cases occur when the CD4 count is below 200, and the risk is highest below 100 cells/µL.
  • Prior episode of PCP: Even with a CD4 count > 200, a history of PCP increases future risk.
  • Oral candidiasis: A marker of advanced immunosuppression.
  • Recurrent bacterial pneumonia: Another indicator of immune compromise.
  • Unexplained fever for > 2 weeks.
  • Weight loss.
• Solid organ transplant recipients: Especially those on immunosuppressive medications (e.g., corticosteroids, calcineurin inhibitors, antimetabolites).
• Haematological malignancies: Such as leukaemia and lymphoma, particularly during chemotherapy or stem cell transplantation.
• Corticosteroid use: High-dose or prolonged systemic corticosteroid therapy for various conditions (e.g., autoimmune diseases, inflammatory conditions).
• Other immunosuppressive conditions or medications:
  • Autoimmune diseases (e.g., SLE, rheumatoid arthritis) treated with immunosuppressants.
  • Primary immunodeficiencies.
  • Malnutrition.

Pathophysiology

Inhalation of Pneumocystis jirovecii cysts/trophozoites → Adherence to alveolar epithelial cells (Type I and II pneumocytes) → Replication of the organism within the alveoli → Host immune response (primarily involving macrophages and residual CD4+ T-cells) attempts to clear the organism, but is ineffective in immunocompromised individuals → Inflammation and accumulation of proteinaceous, foamy exudate within the alveolar spaces → Thickening of the alveolar-capillary membrane and damage to Type I and II pneumocytes → Impaired gas exchange (reduced diffusion capacity for oxygen) → Hypoxemia, V/Q mismatch, and increased work of breathing.

Clinical features

PCP typically presents as a subacute illness, developing over days to weeks, rather than hours. The key to diagnosis lies in a high index of suspicion in at-risk individuals.

History questions that matter:

• Onset and duration of symptoms: "When did your cough start? Has it been getting worse gradually or suddenly?" (Subacute onset over days to weeks is characteristic, differentiating it from acute bacterial pneumonia).
• Nature of cough: "Is your cough dry or do you bring up phlegm?" (Typically a dry, non-productive cough. Productive cough suggests bacterial pneumonia or TB).
• Dyspnoea: "Do you feel short of breath? When does it happen – at rest, or when you exert yourself?" (Exertional dyspnoea is a hallmark, progressing to dyspnoea at rest. This is a key indicator of severity and often precedes significant CXR changes).
• Fever: "Have you had fevers or chills?" (Low-grade fever is common, but high fevers can occur).
• Chest pain: "Do you have any chest pain?" (Usually absent, or non-pleuritic).
• Constitutional symptoms: "Have you lost weight? Do you feel tired all the time? Any night sweats?" (Weight loss, fatigue, and night sweats can be present, overlapping with TB).
• HIV status and CD4 count: "Are you aware of your HIV status? When was your last CD4 count, and what was the result?" (Crucial for risk stratification. PCP typically occurs at CD4 <200 cells/µL, but can occur at higher counts, especially in those on ART with poor adherence or other immunosuppression).
• Prophylaxis history: "Are you currently taking any medication to prevent infections?" (To assess adherence to co-trimoxazole prophylaxis).
• Exposure history: "Have you been in contact with anyone with TB?" (To differentiate from TB).

Examination findings and why each occurs:

• General appearance: Patient may appear anxious, tachypnoeic, and in respiratory distress, especially with exertion. This reflects the impaired gas exchange.
• Vital signs:
  • Tachypnoea: Increased respiratory rate to compensate for hypoxemia.
  • Tachycardia: Due to hypoxemia and increased work of breathing.
  • Fever: Low-grade fever is common due to the inflammatory response.
  • Oxygen saturation (SpO2): Often normal at rest initially, but characteristically desaturates significantly on exertion (e.g., walking a few steps or talking). This is a critical finding, reflecting the impaired oxygen diffusion across the thickened alveolar-capillary membrane, which is exacerbated by increased oxygen demand during activity.
• Chest examination:
  • Inspection: May show increased work of breathing (e.g., accessory muscle use, intercostal recession) in severe cases.
  • Palpation: Normal vocal fremitus.
  • Percussion: Usually resonant, as there is no consolidation or pleural effusion.
  • Auscultation: Often remarkably normal or reveals only fine inspiratory crackles, especially at the bases. This is a key differentiating feature from bacterial pneumonia, where crackles and bronchial breathing are more prominent. The relative paucity of physical signs despite significant respiratory distress and hypoxemia is characteristic of PCP.
• Other findings:
  • Oral thrush (candidiasis): Common in immunocompromised patients, indicating underlying immunosuppression.
  • Lymphadenopathy: Not typically a feature of PCP itself, but may be present due to HIV or other opportunistic infections.

Differential diagnosis

Investigations

Diagnosis and severity

Diagnosis of PCP relies on a combination of clinical suspicion, characteristic radiological findings, and definitive identification of P. jirovecii from respiratory secretions.

1. Clinical suspicion: An immunocompromised patient (especially HIV-positive with CD4 <200 cells/µL) presenting with subacute onset of dry cough, exertional dyspnoea, and fever, with often minimal chest examination findings but significant exertional desaturation.
2. Radiological findings:
   • CXR: Diffuse bilateral interstitial infiltrates, often perihilar. A normal CXR does not rule out early PCP.
   • HRCT Chest: Ground-glass opacities are highly characteristic and more sensitive.
3. Laboratory markers: Elevated LDH and Beta-D-glucan support the diagnosis but are not specific.
4. Definitive diagnosis: Requires microscopic identification of P. jirovecii cysts or trophozoites from respiratory samples.
   • Induced sputum: Less invasive, but lower sensitivity (50-90%).
   • Bronchoalveolar lavage (BAL): The gold standard, with sensitivity >95%. This is usually performed via bronchoscopy.
   • Molecular tests (PCR): Can be used on respiratory samples, highly sensitive, but may detect colonization rather than active infection.

Severity assessment is crucial for guiding treatment, particularly the use of corticosteroids. Severity is primarily determined by the degree of hypoxemia.

• Mild PCP: Room air PaO2 >70 mmHg, or A-a gradient <35 mmHg.
• Moderate PCP: Room air PaO2 <70 mmHg, or A-a gradient ≥35 mmHg.
• Severe PCP: Room air PaO2 <60 mmHg, or A-a gradient ≥45 mmHg, or SpO2 <90% on room air. Patients often require supplemental oxygen.

The A-a gradient is calculated as: P(A-a)O2 = PAO2 - PaO2. PAO2 (alveolar oxygen pressure) = (FiO2 x [Patm - PH2O]) - (PaCO2 / R) Where FiO2 is fraction of inspired oxygen (0.21 for room air), Patm is atmospheric pressure (approx. 760 mmHg at sea level), PH2O is water vapour pressure (47 mmHg), and R is respiratory quotient (0.8).

In clinical practice, SpO2 on room air and the need for supplemental oxygen are the most readily available and practical indicators of severity. Significant desaturation on exertion is an early indicator of impaired gas exchange.

Management

Immediate Stabilisation:

• Oxygen therapy: Essential for hypoxaemia. Titrate to maintain SpO2 >90%.
• Fluid management: Assess hydration status; avoid overhydration in patients with respiratory compromise.
• Analgesia/Antipyretics: For comfort, if indicated.

Definitive Treatment:

• First-line: High-dose co-trimoxazole (trimethoprim-sulfamethoxazole). This is the cornerstone of PCP treatment due to its efficacy against P. jirovecii.
• Alternative regimens (for severe allergy or intolerance to co-trimoxazole):
  • Clindamycin plus primaquine
  • Pentamidine (intravenous)
  • Atovaquone (for mild cases or intolerance to co-trimoxazole)
• Corticosteroids: Indicated in moderate to severe PCP (PaO2 <70 mmHg on room air or A-a gradient >35 mmHg). They reduce inflammation and improve oxygenation. Steroids should be initiated as soon as possible, ideally within 72 hours of starting anti-PCP therapy.

Monitoring and Follow-up:

• Monitor respiratory status (SpO2, respiratory rate, work of breathing).
• Monitor for adverse effects of co-trimoxazole (e.g., rash, bone marrow suppression, hyperkalaemia, hepatotoxicity, renal impairment).
• Clinical improvement is usually seen within 4-8 days. Treatment duration is typically 21 days.
• Follow-up CD4 count to guide prophylaxis decisions.

Contraindications and Safety:

• Co-trimoxazole is contraindicated in severe hypersensitivity reactions.
• Caution with co-trimoxazole in patients with pre-existing renal or hepatic impairment, or G6PD deficiency (risk of haemolysis).
• Pentamidine can cause significant adverse effects including nephrotoxicity, hypoglycaemia, and cardiac arrhythmias.

Complications and Prognosis

• Acute Respiratory Failure: The most common and life-threatening complication, often requiring mechanical ventilation.
• Pneumothorax: Can occur due to rupture of subpleural cysts or blebs.
• Bronchiectasis and Cystic Lung Disease: Long-term sequelae in some survivors.
• Drug Toxicity: Adverse effects from treatment regimens (e.g., bone marrow suppression, renal failure, hepatotoxicity).
• Immune Reconstitution Inflammatory Syndrome (IRIS): Can occur after initiating antiretroviral therapy (ART) in patients with severe immunosuppression, leading to worsening respiratory symptoms.
• Prognosis: Varies significantly with severity at presentation and promptness of treatment. Mortality rates are high in severe cases, especially those requiring mechanical ventilation. With effective ART and prophylaxis, the incidence and mortality of PCP have decreased.

High-yield exam points

• Normal chest examination with severe hypoxaemia is a classic presentation of PCP.
• Steroids are used in moderate to severe PCP (PaO2 <70 mmHg or A-a gradient >35 mmHg) to reduce inflammation and improve oxygenation, in addition to anti-PCP therapy.
• Co-trimoxazole adverse effects: rash, bone marrow suppression (anaemia, leucopenia, thrombocytopenia), hyperkalaemia, renal impairment, hepatotoxicity.
• PCP typically presents with a subacute dry cough and exertional dyspnoea, unlike the acute, productive cough of bacterial pneumonia.
• PCP is a fungal infection, but it does not respond to standard antifungal agents like fluconazole.
• Prophylaxis with co-trimoxazole is indicated for HIV patients with CD4 count <200 cells/µL or a history of PCP.

Clinical case

A 32-year-old HIV-positive male, not on ART, presents with a 3-week history of progressive shortness of breath, dry cough, and low-grade fever. He denies chest pain or haemoptysis. On examination, he is tachypnoeic (RR 28/min), SpO2 88% on room air, and has fine crackles bilaterally on auscultation. His CD4 count is 80 cells/µL. Chest X-ray shows bilateral perihilar interstitial infiltrates.

Question 1

What is the most likely diagnosis?

A. Bacterial pneumonia B. Pulmonary tuberculosis C. Pneumocystis jirovecii pneumonia (PCP) D. Kaposi's sarcoma of the lung

Answer: C. Pneumocystis jirovecii pneumonia (PCP) Explanation: The subacute onset of dry cough and progressive dyspnoea in an HIV-positive patient with a very low CD4 count and bilateral interstitial infiltrates is highly suggestive of PCP.

Question 2

What is the most appropriate initial management step for this patient's hypoxaemia?

A. Start empiric broad-spectrum antibiotics B. Administer high-flow oxygen C. Initiate anti-tuberculous therapy D. Perform bronchoscopy immediately

Answer: B. Administer high-flow oxygen Explanation: The patient is significantly hypoxaemic (SpO2 88%), so immediate oxygen therapy is crucial to improve oxygenation and prevent further respiratory compromise.

Question 3

Given the patient's SpO2, what additional medication should be considered alongside definitive anti-PCP treatment?

A. Systemic corticosteroids B. Nebulized salbutamol C. Intravenous fluids D. Antifungal agents like fluconazole

Answer: A. Systemic corticosteroids Explanation: With an SpO2 of 88% on room air, this patient has moderate to severe PCP, for which systemic corticosteroids are indicated to reduce inflammation and improve outcomes, in addition to co-trimoxazole.

Practice questions

Question 1

A 45-year-old HIV-positive patient, CD4 count 150 cells/µL, presents with a 2-week history of dry cough and exertional dyspnoea. His chest X-ray shows bilateral interstitial infiltrates. Which of the following findings would most strongly support a diagnosis of PCP over bacterial pneumonia?

A. Productive cough with purulent sputum B. Acute onset of high fever and pleuritic chest pain C. Normal chest auscultation despite significant hypoxaemia D. Unilateral lobar consolidation on chest X-ray

Answer: C. Normal chest auscultation despite significant hypoxaemia Explanation: PCP often presents with disproportionately severe hypoxaemia compared to physical examination findings, which can be remarkably normal. Bacterial pneumonia typically has more prominent auscultatory findings.

Question 2

A 30-year-old HIV-positive patient is diagnosed with moderate PCP (PaO2 65 mmHg on room air). Which of the following is the most appropriate initial treatment regimen?

A. High-dose co-trimoxazole alone B. High-dose co-trimoxazole plus systemic corticosteroids C. Intravenous pentamidine alone D. Atovaquone alone

Answer: B. High-dose co-trimoxazole plus systemic corticosteroids Explanation: For moderate to severe PCP (PaO2 <70 mmHg), systemic corticosteroids are indicated in addition to high-dose co-trimoxazole to improve outcomes.

Question 3

Which of the following adverse effects is a common concern when administering high-dose co-trimoxazole for PCP?

A. Hypoglycaemia B. Cardiac arrhythmias C. Hyperkalaemia D. Nephrolithiasis

Answer: C. Hyperkalaemia Explanation: Co-trimoxazole can cause hyperkalaemia, especially in patients with renal impairment or those on other potassium-sparing medications, due to its trimethoprim component.

Question 4

A 28-year-old HIV-positive patient, CD4 count 50 cells/µL, is discharged after successful treatment for PCP. What is the most important long-term management strategy to prevent recurrence?

A. Monthly chest X-rays B. Lifelong oral fluconazole C. Co-trimoxazole prophylaxis D. Annual influenza vaccination only

Answer: C. Co-trimoxazole prophylaxis Explanation: For HIV patients with CD4 count <200 cells/µL or a history of PCP, co-trimoxazole prophylaxis is essential to prevent recurrence.

Question 5

Which of the following features best differentiates PCP from pulmonary tuberculosis (TB) in an HIV-positive patient?

A. Presence of fever B. Subacute onset of symptoms C. Predominantly interstitial infiltrates on chest X-ray D. Rapid clinical response to standard anti-TB drugs

Answer: D. Rapid clinical response to standard anti-TB drugs Explanation: PCP does not respond to anti-TB drugs. While both can present subacutely with fever and interstitial infiltrates, a lack of response to anti-TB treatment (if empirically started) would point away from TB and towards PCP or other opportunistic infections.

Drafted with AI assistance from standard references and reviewed for structure. Check details against your lecture notes and the Kenya MoH guideline.